Acutus Medical Inc. (AFIB): Price and Financial Metrics
AFIB Price/Volume Stats
Current price | $0.26 | 52-week high | $1.09 |
Prev. close | $0.19 | 52-week low | $0.16 |
Day low | $0.18 | Volume | 6,917,900 |
Day high | $0.27 | Avg. volume | 2,600,306 |
50-day MA | $0.20 | Dividend yield | N/A |
200-day MA | $0.47 | Market Cap | 7.68M |
AFIB Stock Price Chart Interactive Chart >
AFIB Stock Summary
- AFIB has a higher market value than just 3.1% of US stocks; more precisely, its current market capitalization is $5,831,452.
- AFIB's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 0.27 -- higher than only 3.35% of US-listed equities with positive expected earnings growth.
- Of note is the ratio of ACUTUS MEDICAL INC's sales and general administrative expense to its total operating expenses; 99.8% of US stocks have a lower such ratio.
- If you're looking for stocks that are quantitatively similar to ACUTUS MEDICAL INC, a group of peers worth examining would be BLUE, AGIO, IMRN, VJET, and ASTR.
- Visit AFIB's SEC page to see the company's official filings. To visit the company's web site, go to www.acutusmedical.com.
AFIB Valuation Summary
- AFIB's price/sales ratio is 0.3; this is 86.36% lower than that of the median Healthcare stock.
- AFIB's EV/EBIT ratio has moved up 7.2 over the prior 41 months.
Below are key valuation metrics over time for AFIB.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
AFIB | 2023-12-29 | 0.3 | 0.2 | -0.2 | -0.5 |
AFIB | 2023-12-28 | 0.3 | 0.2 | -0.2 | -0.5 |
AFIB | 2023-12-27 | 0.3 | 0.2 | -0.2 | -0.5 |
AFIB | 2023-12-26 | 0.3 | 0.2 | -0.2 | -0.5 |
AFIB | 2023-12-22 | 0.3 | 0.2 | -0.2 | -0.5 |
AFIB | 2023-12-21 | 0.3 | 0.2 | -0.2 | -0.5 |
AFIB's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- AFIB has a Quality Grade of F, ranking ahead of 1.4% of graded US stocks.
- AFIB's asset turnover comes in at 0.079 -- ranking 159th of 186 Medical Equipment stocks.
- 500 - Internal server error
The table below shows AFIB's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-06-30 | 0.079 | -0.743 | -0.714 |
2021-03-31 | 0.066 | -0.876 | -0.809 |
2020-12-31 | 0.060 | -0.877 | -0.878 |
AFIB Price Target
For more insight on analysts targets of AFIB, see our AFIB price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $20.67 | Average Broker Recommendation | 1.6 (Moderate Buy) |
Acutus Medical Inc. (AFIB) Company Bio
Acutus Medical develops medical technologies to treat complex cardiac arrhythmia. The company's platform displays the heart’s true activation pattern, turning the chaos of a complex arrhythmia into a clear vision for electrophysiologists. Acutus Medical is a privately funded company founded in 2011 and based in Carlsbad, California. Its products are co-developed in the U.S. and Europe with an exceptional team of medical scientists, biomedical engineers, and other professionals.
Latest AFIB News From Around the Web
Below are the latest news stories about ACUTUS MEDICAL INC that investors may wish to consider to help them evaluate AFIB as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayIt's time to start Tuesday trading with a breakdown of the biggest pre-market stock movers worth keeping an eye on this morning! |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayIt's time to start the day with a breakdown of the biggest pre-market stock movers worth keeping an eye on for Thursday! |
Acutus laying off 65% of employees to focus solely on Medtronic heart device dealThe company has decided to exit the mapping and ablation business and focus its remaining cash on the Medtronic partnership. |
Acutus Medical Inc (AFIB) Reports Substantial Revenue Growth in Q3 2023 Despite Negative Gross ...Improvements in Operating Efficiency and Strategic Partnerships Drive Performance |
Acutus Medical Reports Third Quarter 2023 Financial ResultsCARLSBAD, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB) today reported results for the third quarter of 2023. Recent Highlights: Third quarter revenue of $5.2 million grew 44% year-over-year, led by strong growth in distribution revenue from sales of left-heart access products to MedtronicRegistered significant year-over-year reductions in both GAAP and non-GAAP operating expenses and cash burn, resulting from disciplined focus on expen |
AFIB Price Returns
1-mo | 31.31% |
3-mo | 33.20% |
6-mo | -62.61% |
1-year | -67.90% |
3-year | -98.32% |
5-year | N/A |
YTD | 28.78% |
2023 | -82.44% |
2022 | -66.28% |
2021 | -88.16% |
2020 | N/A |
2019 | N/A |
Loading social stream, please wait...